In the brain, neurons involved in appetite control have devoted GLP-1 receptors
Researchers believe that semaglutide could be a powerful anti-addiction drug, and anecdotal reports indicate that it may help quell compulsive behaviors such as nail-biting and binge shopping
*Correspondence: Boutaina Daher [email protected] Pouyssgur [email protected] This article was submitted to Cancer Metabolism, a section of the journal Frontiers in Oncology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
While promising results have been observed in animal studies and anecdotal reports, comprehensive clinical trials are necessary to establish its safety and efficacy
First Patient Dose Delivered for Lilly's Tirzepatide Cardiovascular Outcomes Trial INDIANAPOLIS, June 9, 2020 /PRNewswire/ -- The first patient dose has been delivered in SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide, Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist
